---
document_datetime: 2025-11-23 08:06:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/taxespira.html
document_name: taxespira.html
version: success
processing_time: 0.1095824
conversion_datetime: 2025-12-27 20:28:44.34434
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Taxespira (previously Docetaxel Hospira UK Limited )

[RSS](/en/individual-human-medicine.xml/67121)

##### Withdrawn

This medicine's authorisation has been withdrawn

docetaxel

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Taxespira (previously Docetaxel Hospira UK Limited )](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 30 October 2018, the European Commission withdrew the marketing authorisation for Taxespira (docetaxel) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Hospira UK Limited, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Taxespira was granted marketing authorisation in the EU on 28 August 2015 for treatment of breast cancer, non small cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer. The marketing authorisation was initially valid for a 5-year period.

Taxespira is a generic medicine of Taxotere. There are other generic medicinal products of Taxotere authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Taxespira is updated to reflect the fact that the marketing authorisation is no longer valid.

Taxespira (previously Docetaxel Hospira UK Limited) : EPAR - Summary for the public

Reference Number: EMA/471475/2015

English (EN) (1.12 MB - PDF)

**First published:** 17/09/2015

**Last updated:** 15/10/2019

[View](/en/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_en.pdf)

[Other languages (23)](#file-language-dropdown-70)

български (BG) (2.23 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/bg/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_bg.pdf)

čeština (CS) (1.77 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/cs/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_cs.pdf)

dansk (DA) (1.07 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/da/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_da.pdf)

Deutsch (DE) (1023.42 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/de/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_de.pdf)

eesti keel (ET) (988.19 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/et/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_et.pdf)

ελληνικά (EL) (3.36 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/el/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_el.pdf)

français (FR) (1015.97 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/fr/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_fr.pdf)

hrvatski (HR) (1.03 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/hr/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_hr.pdf)

íslenska (IS) (1.02 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/is/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_is.pdf)

italiano (IT) (1.05 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/it/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_it.pdf)

latviešu valoda (LV) (1.93 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/lv/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (1.07 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/lt/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_lt.pdf)

magyar (HU) (1.84 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/hu/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_hu.pdf)

Malti (MT) (2.48 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/mt/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_mt.pdf)

Nederlands (NL) (1.08 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/nl/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_nl.pdf)

norsk (NO) (498.38 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/no/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_no.pdf)

polski (PL) (1.88 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/pl/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_pl.pdf)

português (PT) (1.1 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/pt/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_pt.pdf)

română (RO) (1.07 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/ro/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_ro.pdf)

slovenčina (SK) (1.82 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/sk/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_sk.pdf)

slovenščina (SL) (1.99 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/sl/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_sl.pdf)

Suomi (FI) (1.06 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/fi/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_fi.pdf)

svenska (SV) (1012.6 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/sv/documents/overview/taxespira-previously-docetaxel-hospira-uk-limited-epar-summary-public_sv.pdf)

Taxespira (previously Docetaxel Hospira UK Limited) : EPAR - Risk-management-plan summary

English (EN) (1.08 MB - PDF)

**First published:** 17/09/2015

**Last updated:** 15/10/2019

[View](/en/documents/rmp-summary/taxespira-previously-docetaxel-hospira-uk-limited-epar-risk-management-plan-summary_en.pdf)

## Product information

Taxespira : EPAR - Product Information

English (EN) (1.69 MB - PDF)

**First published:** 17/09/2015

**Last updated:** 15/10/2019

[View](/en/documents/product-information/taxespira-epar-product-information_en.pdf)

[Other languages (22)](#file-language-dropdown-517)

български (BG) (2.28 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/bg/documents/product-information/taxespira-epar-product-information_bg.pdf)

español (ES) (928.15 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/es/documents/product-information/taxespira-epar-product-information_es.pdf)

čeština (CS) (1.77 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/cs/documents/product-information/taxespira-epar-product-information_cs.pdf)

dansk (DA) (937.06 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/da/documents/product-information/taxespira-epar-product-information_da.pdf)

eesti keel (ET) (902.47 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/et/documents/product-information/taxespira-epar-product-information_et.pdf)

ελληνικά (EL) (2.43 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/el/documents/product-information/taxespira-epar-product-information_el.pdf)

français (FR) (918.22 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/fr/documents/product-information/taxespira-epar-product-information_fr.pdf)

hrvatski (HR) (902.41 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/hr/documents/product-information/taxespira-epar-product-information_hr.pdf)

íslenska (IS) (912.96 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/is/documents/product-information/taxespira-epar-product-information_is.pdf)

italiano (IT) (959.09 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/it/documents/product-information/taxespira-epar-product-information_it.pdf)

latviešu valoda (LV) (1.88 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/lv/documents/product-information/taxespira-epar-product-information_lv.pdf)

lietuvių kalba (LT) (937.79 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/lt/documents/product-information/taxespira-epar-product-information_lt.pdf)

magyar (HU) (1.79 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/hu/documents/product-information/taxespira-epar-product-information_hu.pdf)

Malti (MT) (2.44 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/mt/documents/product-information/taxespira-epar-product-information_mt.pdf)

Nederlands (NL) (958.2 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/nl/documents/product-information/taxespira-epar-product-information_nl.pdf)

norsk (NO) (346.58 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/no/documents/product-information/taxespira-epar-product-information_no.pdf)

polski (PL) (1.82 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/pl/documents/product-information/taxespira-epar-product-information_pl.pdf)

português (PT) (1013.98 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/pt/documents/product-information/taxespira-epar-product-information_pt.pdf)

slovenčina (SK) (1.78 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/sk/documents/product-information/taxespira-epar-product-information_sk.pdf)

slovenščina (SL) (1.81 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/sl/documents/product-information/taxespira-epar-product-information_sl.pdf)

Suomi (FI) (939.75 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/fi/documents/product-information/taxespira-epar-product-information_fi.pdf)

svenska (SV) (916.71 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/sv/documents/product-information/taxespira-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0011 30/10/2018

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Taxespira (previously Docetaxel Hospira UK Limited) : EPAR - All Authorised presentations

English (EN) (590.87 KB - PDF)

**First published:** 17/09/2015

**Last updated:** 15/10/2019

[View](/en/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-129)

български (BG) (645.62 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/bg/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_bg.pdf)

español (ES) (591.92 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/es/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_es.pdf)

čeština (CS) (636.63 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/cs/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (594.49 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/da/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (593.47 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/de/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (588.84 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/et/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (648.09 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/el/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_el.pdf)

français (FR) (591.08 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/fr/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (624.98 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/hr/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (590.71 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/is/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_is.pdf)

italiano (IT) (591.46 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/it/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (637.28 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/lv/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (619.35 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/lt/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (619.77 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/hu/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (1.19 MB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/mt/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (592.62 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/nl/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (591.82 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/no/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_no.pdf)

polski (PL) (635.99 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/pl/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_pl.pdf)

português (PT) (593.21 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/pt/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_pt.pdf)

română (RO) (619.5 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/ro/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (635.8 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/sk/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (618.1 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/sl/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (589.67 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/fi/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (589.99 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

15/10/2019

[View](/sv/documents/all-authorised-presentations/taxespira-previously-docetaxel-hospira-uk-limited-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Taxespira (previously Docetaxel Hospira UK Limited ) Active substance docetaxel trihydrate International non-proprietary name (INN) or common name docetaxel Therapeutic area (MeSH)

- Stomach Neoplasms
- Prostatic Neoplasms
- Breast Neoplasms
- Head and Neck Neoplasms
- Carcinoma, Non-Small-Cell Lung

Anatomical therapeutic chemical (ATC) code L01CD02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

**Breast cancer**

Taxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:

- operable node-positive breast cancer;
- operable node-negative breast cancer.

For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.

Taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.

Taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.

Taxespira combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.

Taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.

**Non-small cell lung cancer**

Taxespira indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.

Taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.

**Prostate cancer**

Taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.

**Gastric adenocarcinoma**

Taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.

**Head and neck cancer**

Taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

## Authorisation details

EMA product number EMEA/H/C/003925

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Hospira UK Limited

Horizon, Honey Lane

Opinion adopted 20/05/2015 Marketing authorisation issued 28/08/2015 Withdrawal of marketing authorisation 30/10/2018 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Taxespira (previously Docetaxel Hospira UK Limited) : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (521.39 KB - PDF)

**First published:** 02/02/2016

**Last updated:** 15/10/2019

[View](/en/documents/procedural-steps-after/taxespira-previously-docetaxel-hospira-uk-limited-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Docetaxel Hospira UK Limited : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/289489/2015

English (EN) (1.08 MB - PDF)

**First published:** 17/09/2015

**Last updated:** 15/10/2019

[View](/en/documents/assessment-report/docetaxel-hospira-uk-limited-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Docetaxel Hospira UK Limited

Adopted

Reference Number: EMA/CHMP/289487/2015

English (EN) (698.21 KB - PDF)

**First published:** 26/06/2015

**Last updated:** 15/10/2019

[View](/en/documents/smop-initial/chmp-summary-opinion-docetaxel-hospira-uk-limited_en.pdf)

#### News on Taxespira (previously Docetaxel Hospira UK Limited )

[PRAC concludes there is no evidence of a change in known risk of neutropenic enterocolitis with docetaxel](/en/news/prac-concludes-there-no-evidence-change-known-risk-neutropenic-enterocolitis-docetaxel) 09/06/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2015) 26/06/2015

**This page was last updated on** 15/10/2019

## Share this page

[Back to top](#main-content)